Sumatriptan succinate

Sumatriptan succinate (CAS 103628-48-4) is the succinate salt form of sumatriptan, a selective serotonin receptor agonist used as the active pharmaceutical ingredient in acute migraine and cluster headache treatments.

The salt form offers improved stability and solubility characteristics that are critical for pharmaceutical dosage form development. The primary application is as an API in prescription migraine therapies.

It is formulated into tablets, nasal sprays, and subcutaneous injection products for rapid symptom relief. Pharmaceutical manufacturers source this compound for solid oral dosage forms where precise particle size is required.

Polymorphic consistency directly affects bioavailability and dissolution performance in these formulations. Contract development organizations use it in reformulation projects targeting modified-release or needle-free delivery platforms.

It is also procured by generic drug manufacturers developing bioequivalent products to reference-listed branded formulations. The material is available as a white to off-white crystalline powder for industrial use.

It is supplied in pharmaceutical-grade specifications conforming to USP and BP monographs. Documentation packages typically include CoA, DMF references, and ICH-compliant impurity profiles.

Packaging is offered in quantities ranging from research-scale grams to commercial kilogram lots. This ensures flexibility for both pilot-scale development and full-scale commercial manufacturing requirements.